What are the indications of Upatinib/Refu and what diseases are treated?

Upadacitinib (Upadacitinib) is a representative oral JAK inhibitor developed by the American company AbbVie and promoted globally. The drug selectively inhibits JAK1 enzyme activity and blocks multiple inflammatory signaling pathways, thereby achieving precise regulation of excessive activation of the immune system. Upadatinib has a wide range of indications and is currently approved in Europe, the United States and many countries for the treatment of immune-mediated diseases such as rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, atopic dermatitis, etc. Its clinical positioning is mainly aimed at patients with moderately to severely active disease, especially those who do not respond well to traditional DMARDs or biologics.

In the field of rheumatism and immunity, upadatinib, as a JAK1 selective inhibitor, can effectively reduce the release of inflammatory factors, improve joint pain and swelling, and delay structural damage. Compared with traditional immunosuppressants, it has advantages in speed of onset of action and convenience of oral administration. In dermatology, upadatinib is used to treat moderate to severe atopic dermatitis and chronic eczema, helping to reduce skin itching, erythema and skin lesion area, and significantly improving patients' quality of life. In addition, for digestive system diseases, such as Crohn's disease and ulcerative colitis, it inhibits intestinal immune response, reduces mucosal inflammation, and improves abdominal pain, diarrhea and other symptoms, gradually becoming a representative of a new generation of oral targeted treatment options.

In recent years, the scope of indications for upadatinib has continued to expand, and many European and American countries have approved its use in adolescent atopic dermatitis and non-infectious rheumatism. Its broad-spectrum anti-inflammatory effect and good oral tolerance enable it to demonstrate long-term efficacy and high patient compliance in the management of immune diseases. With the increasing global emphasis on precision treatment of immune diseases, the clinical use trend of upadatinib continues to rise, becoming a highly competitive member of the JAK inhibitor family after tofacitinib and baricitinib.

Reference materials:https://www.rinvoq.com/